2023 World Conference on Lung Cancer (Posters)-EP13.07. Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others

EP13.07. Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others - PDF(Slides)

Back to course

Pdf Summary

This study explored the outcomes of second-line therapy for small cell lung cancer (SCLC) with brain metastasis, specifically comparing the effectiveness of Lurbinectedin with other treatments. 82 patients from the Inova Schar Cancer Institute were included in the analysis. The patients' data was extracted from electronic health records (EHR) and supplemented with manual chart review. The study included patients who received second-line therapy between January 2015 and December 2022.<br /><br />The background of the study suggests that Lurbinectedin has recently been used as a second-line therapy for relapsed or refractory SCLC, but its effectiveness in cases with brain metastasis is not well understood. Previously, Topotecan was the first FDA-approved second-line therapy for SCLC, but Lurbinectedin is now being used more frequently. However, the comparison of Lurbinectedin with other treatments such as Irinotecan has not been thoroughly examined in SCLC patients with brain metastasis.<br /><br />The results of the study showed that out of the 20 patients included in the analysis, 14 discontinued treatment due to disease progression. Among the patients with brain metastasis, those who received Lurbinectedin stayed on treatment for a longer duration compared to those who received other second-line treatments, such as Topotecan. The median progression-free survival (PFS) in the Lurbinectedin group was 150 days, whereas it was 122 days in patients on other treatments.<br /><br />In conclusion, patients with brain metastasis from SCLC have a poor prognosis. This study, although limited by a small sample size, suggests that Lurbinectedin may be more effective than the previous standard treatment, Topotecan. Further research is needed to evaluate the role of other therapies, such as Irinotecan, and to compare the survival effects of Lurbinectedin, Topotecan, and Irinotecan. The use of robust EHR data can aid in selecting appropriate treatments for patients with relapsed or progressive SCLC, with or without brain metastasis.

Asset Subtitle

Faran Polani

Meta Tag

Speaker Faran Polani

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

second-line therapy

small cell lung cancer

SCLC

brain metastasis

Lurbinectedin

treatments

effectiveness

Topotecan

Irinotecan

progression-free survival